Pulse Biosciences, Inc.
PLSE
$13.18
-$0.07-0.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 47.53% | 82.10% | 99.56% | 102.77% | 57.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.78% | 72.91% | 69.99% | 61.66% | 21.36% |
| Operating Income | -49.15% | -72.91% | -69.99% | -61.66% | -21.36% |
| Income Before Tax | -52.88% | -68.39% | -65.68% | -62.45% | -20.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.88% | -68.39% | -65.68% | -62.45% | -20.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.88% | -68.39% | -65.68% | -62.45% | -20.01% |
| EBIT | -49.15% | -72.91% | -69.99% | -61.66% | -21.36% |
| EBITDA | -50.52% | -75.03% | -72.17% | -63.33% | -21.98% |
| EPS Basic | -38.58% | -43.09% | -40.96% | -44.16% | -11.73% |
| Normalized Basic EPS | -38.52% | -43.17% | -41.03% | -44.06% | -11.80% |
| EPS Diluted | -38.58% | -43.09% | -40.96% | -44.16% | -11.73% |
| Normalized Diluted EPS | -38.52% | -43.17% | -41.03% | -44.06% | -11.80% |
| Average Basic Shares Outstanding | 10.35% | 17.66% | 17.51% | 12.71% | 7.39% |
| Average Diluted Shares Outstanding | 10.35% | 17.66% | 17.51% | 12.71% | 7.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |